MSD and Daiichi Sankyo have announced first subject dosing in the randomised IDeate-Prostate01 Phase III trial of ifinatamab ...

Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial ...

Merck just kicked off its Phase 3 IDeate-Prostate01 trial, handing the first dose of ifinatamab deruxtecan to a patient ...

Three United Nations agencies warned on Thursday of looming famine in an area of South Sudan facing violent conflict. People in 11 of 13 counties in South Sudan’s Upper Nile ...

MacroGenics' recent royalty deal extends cash runway, but liquidity concerns remain, and further asset sales or dilution may ...

The Palestinian Health Ministry says Palestinians desperately trying to access aid in Gaza have come under fire again, killing 36 people and wounding 207. Experts and humanitarian aid workers say ...

映恩生物-B（09606）早盘一度涨超13%，盘中高见243.2港元，创上市新高。截至发稿，股价上涨11.66%，报239.40港元，成交额8327.82万港元。

再鼎医药算是本次ASCO大会上最靓的仔之一，DLL3 ADC同时兼具全球first in class兼具best in ...

SHANGHAI, China and CHICAGO, IL, USA I June 5, 2025 I The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio ...

Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers Data completes ...

基于中国B7-H3 抗体行业历史发展规律、发展环境与行业整体发展态势来看，报告给出了过去五年内全球B7-H3 抗体市场规模变化趋势并预计了2024-2030年B7-H3 抗体市场规模与年复合增长率。2024年全球B7-H3 抗体市场营收达到了 亿元（人民币）。根据B7-H3 抗体行业发展 ...

免疫检查点阻断（ICB）对多数结直肠癌患者临床响应有限。研究人员开展靶向 B7-H3 增强新抗原癌症疫苗联合放疗疗效的研究，发现靶向 B7-H3 可提升疗效、降低远处肿瘤风险，为免疫治疗耐药癌症提供新策略。 在癌症治疗领域，免疫疗法近年来取得了不少进展 ...